CSL (OTCMKTS:CSLLY) Trading 1% Higher - Here's Why

Key Points

• Shares of CSL Limited (OTCMKTS:CSLLY) increased by 1% to close at $69.00 after trading as high as $69.98.
• Analysts have mixed opinions on the stock, with Zacks Research downgrading CSL to a "strong sell" while Canaccord Genuity upgraded it to a "hold".
• CSL operates in the biopharmaceutical and vaccine sector with a current ratio of 2.46 and a debt-to-equity ratio of 0.50.

Shares of CSL Limited Sponsored ADR (OTCMKTS:CSLLY - Get Free Report) traded up 1% on Tuesday . The stock traded as high as $69.98 and last traded at $69.00. 172,552 shares changed hands during trading, an increase of 6% from the average session volume of 162,760 shares. The stock had previously closed at $68.31.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Zacks Research cut CSL from a "hold" rating to a "strong sell" rating in a research note on Monday, September 15th. Canaccord Genuity Group upgraded CSL to a "hold" rating in a research note on Monday, October 6th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold".

CSL Price Performance

The company has a quick ratio of 1.12, a current ratio of 2.46 and a debt-to-equity ratio of 0.50. The stock has a 50 day simple moving average of $71.46 and a two-hundred day simple moving average of $76.80.

About CSL

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.